|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300077884 |
|
最近更新日期: Date of Last Refreshed on: |
2023-11-22 16:32:13 |
|
注册时间: Date of Registration: |
2023-11-22 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
睡前听觉心率变异性生物反馈对失眠患者睡眠效率的影响 |
|
Public title: |
The Impact of Pre-Sleep Auditory Heart Rate Variability Biofeedback on Sleep Efficiency in Insomnia Patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
睡前听觉心率变异性生物反馈对失眠患者睡眠效率的影响 |
|
Scientific title: |
The Impact of Pre-Sleep Auditory Heart Rate Variability Biofeedback on Sleep Efficiency in Insomnia Patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王鹏 |
研究负责人: |
王鹏 |
|
Applicant: |
Peng Wang |
Study leader: |
Peng Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 10 8839 6213 |
研究负责人电话: Study leader's telephone: |
+86 10 8839 6213 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wpeng333@outlook.com |
研究负责人电子邮件: Study leader's E-mail: |
wpeng333@outlook.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国北京市西城区北礼士路167号 |
研究负责人通讯地址: |
中国北京市西城区北礼士路167号 |
|
Applicant address: |
No.167 North Lishi Road, Xicheng District, Beijing, China |
Study leader's address: |
No.167 North Lishi Road, Xicheng District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国医学科学院阜外医院 |
||
|
Applicant's institution: |
Fuwai Hospital Chinese Academy of Medical Sciences |
||
|
研究负责人所在单位: |
中国医学科学院阜外医院 |
||
|
Affiliation of the Leader: |
Fuwai Hospital Chinese Academy of Medical Sciences |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023-2050 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国医学科学院阜外医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Fuwai Hospital, CAMS&PUMC |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-07-11 00:00:00 |
||
|
伦理委员会联系人: |
高楠 |
||
|
Contact Name of the ethic committee: |
Nan Gao |
||
|
伦理委员会联系地址: |
中国北京市西城区北礼士路167号 |
||
|
Contact Address of the ethic committee: |
No.167 North Lishi Road, Xicheng District, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 8839 6281 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国医学科学院阜外医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Fuwai Hospital Chinese Academy of Medical Sciences |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国北京市西城区北礼士路167号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.167 North Lishi Road, Xicheng District, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中央高水平医院临床科研业务费资助 (No. 2023-GSP-QN-22) |
||||||||||||||||||||||
|
Source(s) of funding: |
the National High Level Hospital Clinical Research Funding (No. 2023-GSP-QN-22) |
||||||||||||||||||||||
|
Target disease: |
insomnia disorder |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
本研究旨在探索一种非药物治疗失眠的方法,即采用光电容积技术的睡前听觉心率变异性生物反馈,通过训练改善失眠患者的睡前状态,进而改善睡眠效率,改善患者的生活质量。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to explore a non-pharmacological approach for treating insomnia, using pre-sleep auditory heart rate variability biofeedback based on photoplethysmography technology. Through training, it aims to improve the pre-sleep state of insomnia patients, thereby enhancing sleep efficiency and overall quality of life. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1)年龄:20-45岁,性别不限; 2)人群范围:经DSM-5诊断标准确诊的失眠障碍人群; 3)具有一定沟通及理解能力; 4)已签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1)Age: 20-45 years old, gender unrestricted; 2)Target Population: Individuals diagnosed with insomnia disorder based on the diagnosis criteria of DSM-5; 3)Possess adequate communication and comprehension abilities; 4)Have signed informed consent. |
||||||||||||||||||||||
|
排除标准: |
1)根据DSM-5诊断标准确诊的有精神合并症或躯体合并症,或其他睡眠障碍的患者; 2)妊娠或备孕期女性; 3)使用助眠药物和/或营养补充剂者; 4)患有急性心肌梗死、急性快速心律失常、肺水肿、重度主动脉瓣狭窄等急性心脑血管疾病者; 5)患有哮喘、慢性阻塞性肺疾病(COPD)、肺容量受限(由于肥胖、妊娠或脊柱畸形)或囊性纤维化等严重的呼吸系统疾病者; 6)内分泌和代谢疾病,包括甲亢、肝功能衰竭和肾脏疾病等; 7)神经肌肉疾病和退行性病变,如肌营养不良症、脊髓灰质炎和痴呆症等; 8)运动和其他神经系统疾病,如亨廷顿病、扭转性肌张力障碍、帕金森氏病以及某些癫痫疾病; 9)设备测量部位周围有皮肤疾病或损伤; 10)过敏体质等情况; 11)正在参与的药物或器械临床试验; 12)拒绝签署知情同意书。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1)Patients diagnosed with mental or physical comorbidities, or other sleep disorders according to the diagnostic criteria of DSM-5; 2)Pregnant or pre-pregnant females; 3)Individuals using sleep aids and/or nutritional supplements; 4)Patients suffering from acute cardiovascular and cerebrovascular conditions such as acute myocardial infarction, acute rapid arrhythmias, pulmonary edema, severe aortic valve stenosis, etc.; 5)Individuals with severe respiratory ailments such as asthma, chronic obstructive pulmonary disease (COPD), restricted lung capacity (due to obesity, pregnancy, or spinal deformities), or cystic fibrosis; 6)Endocrine and metabolic disorders, including hyperthyroidism, liver failure, and kidney diseases, etc.; 7)Neuromuscular diseases and degenerative conditions, such as muscular dystrophy, spinal muscular atrophy, and dementia, etc.; 8)Movement and other neurological disorders, such as Huntington's disease, dystonia, Parkinson's disease, and epilepsy disorders; 9)Patients with skin diseases or injuries around the device measurement sites; 10)Individuals with allergic predispositions, etc.; 11)Participants currently involved in drug or medical device clinical trials; 12)Individuals refusing to provide informed consent. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-06-30 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-11-30 00:00:00 至 To 2024-11-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究未设置对照组,未进行随机化 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study did not include a control group and was not randomized. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
合理需求下可向负责人申请数据共享权限。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The data are available to researchers on reasonable request from the corresponding author for the purpose of reproducing results or replicating the procedure. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
为了保证数据采集质量的准确性和真实性,研究团队统一进行数据质控培训。数据导出过程遵循保密原则,导出的数据库由本研究的研究者在不连接外网的电脑单独存储,确保数据库不对外泄漏。信息化提取临床检查数据和穿戴设备数据,整理采集的随访数据,建立数据库。数据将采取双人录入,安排专门人员检查缺失值、异常值以及逻辑错误等问题,有效避免数据录入过程中的错误,通过软件数据比对功能合并数据库。对于可穿戴设备数据每天核查是否正常监测状态。受试者睡眠日记需每周上传核查,如无填写及时要求完善。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
To ensure the accuracy and authenticity of data collection, the research team underwent unified data quality control training. The data export process followed confidentiality principles, with the exported database stored separately by the researchers involved in the study on computers not connected to the internet, ensuring non-disclosure of the database to external parties. Clinical examination data and wearable device data were extracted through information technology, and follow-up data was organized to establish the database. Data entry was performed by two individuals, with designated personnel checking for missing values, outliers, and logical errors to effectively prevent errors during data entry. Database merging was done using software data comparison functions. Wearable device data were checked daily to ensure normal monitoring status. Participants were required to upload and verify their sleep diaries weekly; if not filled out, timely completion was requested. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |